Cargando…

Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? An observational study from the Nordic countries

OBJECTIVES: The positioning of secukinumab in the treatment of axial SpA (axSpA) and PsA is debated, partly due to a limited understanding of the comparative safety of the available treatments. We aimed to assess the risk of the key safety outcome infections during treatment with secukinumab and TNF...

Descripción completa

Detalles Bibliográficos
Autores principales:	Glintborg, Bente, Di Giuseppe, Daniela, Wallman, Johan K, Provan, Sella A, Nordström, Dan, Hokkanen, Anna-Mari, Österlund, Jenny, Kristianslund, Eirik, Kvien, Tore K, Gudbjornsson, Bjorn , Hetland, Merete Lund, Michelsen, Brigitte, Jacobsson, Lennart, Askling, Johan , Lindström, Ulf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891432/ https://www.ncbi.nlm.nih.gov/pubmed/35723604 http://dx.doi.org/10.1093/rheumatology/keac358

Ejemplares similares

Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example
por: Chatzidionysiou, Katerina, et al.
Publicado: (2018)

Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis
por: Lindström, Ulf, et al.
Publicado: (2019)

Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration
por: Delcoigne, Bénédicte, et al.
Publicado: (2022)

Correction to: Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration
por: Delcoigne, Bénédicte, et al.
Publicado: (2022)

Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries
por: Delcoigne, Benedicte, et al.
Publicado: (2022)

How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers
por: Chatzidionysiou, Katerina, et al.
Publicado: (2020)

Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?
por: Lindström, Ulf, et al.
Publicado: (2021)

Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registers
por: Delcoigne, Benedicte, et al.
Publicado: (2023)

Haematological malignancies in patients with psoriatic arthritis overall and treated with TNF inhibitors: a Nordic cohort study
por: Cordtz, Rene Lindholm, et al.
Publicado: (2022)

Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration
por: Michelsen, Brigitte, et al.
Publicado: (2020)

Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
por: Michelsen, Brigitte, et al.
Publicado: (2023)

Methotrexate treatment in early psoriatic arthritis in comparison to rheumatoid arthritis: an observational nationwide study
por: Lindström, Ulf, et al.
Publicado: (2023)

Does a mandatory non-medical switch from originator to biosimilar infliximab lead to increased use of outpatient healthcare resources? A register-based study in patients with inflammatory arthritis
por: Glintborg, Bente, et al.
Publicado: (2018)

Remission, response, retention and persistence to treatment with disease-modifying agents in patients with rheumatoid arthritis: a study of harmonised Swedish, Danish and Norwegian cohorts
por: Westerlind, Helga, et al.
Publicado: (2023)

Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique?
por: Mongin, Denis, et al.
Publicado: (2019)

The association between disease activity and NT-proBNP in 238 patients with rheumatoid arthritis: a 10-year longitudinal study
por: Provan, Sella A, et al.
Publicado: (2008)

The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab
por: Provan, Sella Aarrestad, et al.
Publicado: (2015)

Rheumatology congresses post COVID-19: we cannot regress
por: Nordberg, Lena Bugge, et al.
Publicado: (2023)

Childhood hospitalisation with infections and later development of ankylosing spondylitis: a national case-control study
por: Lindström, Ulf, et al.
Publicado: (2016)

Assessment of immunogenicity and drug activity in patient sera by flow-induced dispersion analysis
por: Pedersen, Morten E., et al.
Publicado: (2022)

Commonalities and differences in set-up and data collection across European spondyloarthritis registries — results from the EuroSpA collaboration
por: Linde, Louise, et al.
Publicado: (2023)

The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study
por: Ljung, Lotta, et al.
Publicado: (2014)

Perinatal characteristics, older siblings, and risk of ankylosing spondylitis: a case–control study based on national registers
por: Lindström, Ulf, et al.
Publicado: (2016)

Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis
por: Glintborg, Bente, et al.
Publicado: (2019)

Course and predictors of work productivity in gout — results from the NOR-Gout longitudinal 2-year treat-to-target study
por: Uhlig, Till, et al.
Publicado: (2023)

Identification of new biomarkers to promote personalised treatment of patients with inflammatory rheumatic disease: protocol for an open cohort study
por: Kringelbach, Tina Marie, et al.
Publicado: (2018)

Risk of pre-eclampsia and impact of disease activity and antirheumatic treatment in women with rheumatoid arthritis, axial spondylarthritis and psoriatic arthritis: a collaborative matched cohort study from Sweden and Denmark
por: Secher, Anne Emilie Pape, et al.
Publicado: (2022)

Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study
por: Christensen, Ingrid Egeland, et al.
Publicado: (2022)

Discontinuation rate of sulfasalazine, leflunomide and methotrexate due to adverse events in a real-life setting (NOR-DMARD)
por: Mielnik, Pawel, et al.
Publicado: (2023)

Efficacy of High Intensity Exercise on Disease Activity and Cardiovascular Risk in Active Axial Spondyloarthritis: A Randomized Controlled Pilot Study
por: Sveaas, Silje Halvorsen, et al.
Publicado: (2014)

Trajectories of fatigue in actively treated patients with established rheumatoid arthritis starting biologic DMARD therapy
por: Provan, Sella Aarrestad, et al.
Publicado: (2020)

Fatigue is cross-sectionally not associated with objective assessments of inflammation, but changes in fatigue are associated with changes of disease activity assessments during biologic treatment of patients with established rheumatoid arthritis
por: Hammer, Hilde Berner, et al.
Publicado: (2020)

Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration
por: Lindström, Ulf, et al.
Publicado: (2021)

Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries
por: Lauper, Kim, et al.
Publicado: (2018)

Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study
por: Bengtsson, Karin, et al.
Publicado: (2017)

Characteristics and outcome of a first acute myocardial infarction in patients with ankylosing spondylitis
por: Södergren, Anna, et al.
Publicado: (2020)

Incidence of extra-articular manifestations in ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis: results from a national register-based cohort study
por: Bengtsson, Karin, et al.
Publicado: (2020)

Is Nephrolithiasis an Unrecognized Extra-Articular Manifestation in Ankylosing Spondylitis? A Prospective Population-Based Swedish National Cohort Study with Matched General Population Comparator Subjects
por: Jakobsen, Ane Krag, et al.
Publicado: (2014)

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
por: Coates, Laura C., et al.
Publicado: (2019)

The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study
por: Exarchou, Sofia, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_18pkbgsegcllsv1po4o9v87chb